Ondine Biomedical Inc. (AIM:OBI)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 59.75M +38.3% |
| Revenue (ttm) | 1.18M +34.8% |
| Net Income | -12.79M |
| EPS | -0.03 |
| Shares Out | 519.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,201 |
| Average Volume | 478,800 |
| Open | 11.46 |
| Previous Close | 11.25 |
| Day's Range | 11.25 - 11.60 |
| 52-Week Range | 7.50 - 18.50 |
| Beta | 0.22 |
| RSI | 83.25 |
| Earnings Date | May 21, 2026 |
About Ondine Biomedical
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as ... [Read more]
Financial Performance
In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.
Financial numbers in CAD Financial StatementsNews
Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial
VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical announces that it is accelerating its US Phase 3 trial following its recent successful raise of Cdn $16 million (£9m, US $11m).